


### **Genome Metrics**

Scott D. Kahn, PhD Chief Information Officer



### **Data Quality Defined by Metrics Evaluated**

- Read-level quality
  - Quality scores and consensus accuracy
  - GC content and uniformity of representation
- Coverage/gap analysis
  - Biological relevance can be a critical lens
- False positive and false negative call rates
  - SNV's, Indels, rearrangements, ...
- Storage implications
  - Interplay between base quality, depth of coverage, and storage required







### Improving Read Quality

### Reducing Density-Dependent CG Bias

New cluster amp method equalizes growth of AT and GC rich clusters



### **Improving Base Accuracy**



New Scan Reagent (SRE) also reduces signal decay

\*Preliminary




### **Informatics Improvements**

- Alignment Improvements in ELANDv2e
  - Repeat resolution using overlapping seeds
    - Improves coverage over repeat regions
  - Orphan aligner: reads that have multiple mappings, but have read partners which map uniquely, are realigned and scored
    - Increases coverage (% aligned reads: 5–7% more reads)
    - Improves indel detection
- Indel detection (up to 300 bp) and variant calling (SNPs and indels) improvements




- Provides a predicted diploid genotype for every position in genome
- Intersecting reads from the following two sources are realigned to generate accurate indel calls
  - Output of gapped alignment from ELANDv2e
  - Output of IndelFinder (Grouper algorithm)
- Significant reduction in processing time due to multiple optimizations
- Multiple architecture improvements described in detailed documentation (available on iCom and SEQanswers)
- CASAVA 1.8 is in early-access currently






# Assessing Quality/Performance of a Genome

## Tighter Distributions Reduce Data Requirements – NA18507, Chr 21



#### GAllx+TruSeq

Mean mapped coverage (Chr 21) = 32.55 4.44% ref. bases at low coverage (<=15x) IQR = 11 0.45% ref. bases of 0 read



#### HiSeq2000+TruSeq v3


Mean mapped coverage (Chr 21) = 32.49 3.8% ref. bases at low coverage (<=15x) IQR = 10 0.43% ref. bases of 0 read



<sup>1.</sup> Only uniquely mapped reads were considered (MAPQ>1)


<sup>3 2. 13,023,253</sup> Ns in NCBI build 37 were excluded

# Uniform (GC) Coverage Reduces Data Requirements – NA18507, Chr 21






## Improved Alignment Better Levers Existing Data – NA19240, Chr 21



# Improved Coverage Reduces Data Requirements - NA18507, whole genome




- 1. Core ADME gene list from <a href="http://pharmaadme.org/joomla/index.php?option=com-content&task=view&id=12&Itemid=27">http://pharmaadme.org/joomla/index.php?option=com-content&task=view&id=12&Itemid=27</a>
- 2. CYP gene family from <a href="http://www.genenames.org/genefamily/cyp.php">http://www.genenames.org/genefamily/cyp.php</a>



### Gaps in Challenging/Biologically Interesting Genomic Areas

### - NA18507, whole genome








# Sequencing in a Clinical Laboratory


### Individual Genome Sequencing in a Clinical Laboratory

- ▶ Illumina established a protocol for sequencing whole genomes
  - Using Professional and Regulatory agency guidelines
  - Under advisement from an external Ethics Advisory Board
  - Geneticists, Clinicians, Ethicists and Attorneys participated in design of protocol
- Our protocol and validations were evaluated externally
  - CLIA certified for high complexity testing
  - CAP accredited
- Elements of the protocol
  - Process workflow and safety checks
  - Technical validation of the assay
  - Providing a human genome deliverable

### **Assessment of Accuracy**

- ▶ 14 samples of known Factor V genotype sequenced at >6 million-fold depth
- 100% accuracy in genotype calls
- ▶ Sub-sampled 100,000 times at various folds of coverage:





#### Sensitivity

At average 30 fold coverage: 100% for hom./98.89% for het

\* P(x, p, N)=
$$\sum_{k=x}^{N-x} \frac{N!}{(X!)(N-X)!} p^{X}q^{(N-X)}$$

#### **Specificity**

At average 30 fold coverage: 100%




### **Concluding Remarks**

### **Data Management Burden**

ONGOING REDUCTION THE DATA FOOTPRINT
STREAMLINING DATA ANALYSIS
INCREASING COMPUTATIONAL PERFORMANCE

Mapping	Bytes / Base	Data Size 30X Genome	
Pipeline (2008)	30	3,000 GB	
CASAVA (2009)	14	1,400 GB	
CASAVA (2010)	6	600 GB	
Summarized (2011+)	.1	~10 GB	

CASAVA 1.8 uses 1 byte/base



### Structural Variants and FP/FN Rates

Accuracy Metric	Sensitivity			Specificity		
Туре	Simulated data	dbSNP <sup>1</sup>	1000 Genomes <sup>2</sup>	Simulated data		
Small variant						
SNV		97%				
Insertion	>90%	63%	>60%			
Deletion	80%		>30%			
Structural variant						
Large insertion	80%	n/v	2%	>90%		
Large deletion	>80%	n/v	30%	>90%		
Inversion	50%	n/v	n/v	>90%		
Tandem duplication	40-45%	n/v		>95%		
Translocation		n/v	n/v			
Copy number variant						
CNV gain	74%	n/v		100%		
CNV loss	33%	n/v	>15%	77%		

<sup>1.</sup> dbSNP: For SNVs, A subset of 245,469 SNPs were identified as being present in dbSNP130 and further validated by a capillary sequencing study in NA19240 and at least one other Yoruban individual (of NA18506, NA18507 and NA18508) reported in Nature 2008 453(7191):56-64. For indels, a subset of 31,665 indels were identified and validated in the same study.

<sup>2. 1000</sup> Genomes: For insertions, a set of 562 validated SVs were extracted from the Pilot 2 study of 1000 Genome project.

<sup>3.</sup> For deletions, a set of 9695 validated deletions were extracted from the Pilot 2 study of 1000 Genome project.
For CNV loss, a set of 480 CNVs were identified by SOLiD sequencing on NA19240 in the subproject led by Applied Bioscience as part of 1000 Genomes project, and were further validated by at least one low-throughput assay (Mills et al. Nature 2011 470:59-65)